Developing Next Generation, Continuous Glucose Monitoring Systems for People with Diabetes
GlySens Incorporated is a privately held corporation devoted to developing the world’s first truly long term continuous glucose monitoring system, intended to dramatically improve the lives of people with diabetes. The GlySens fully implanted sensor—demonstrated up to 18 month lifetime in preclinical testing—wirelessly links to a convenient external receiver, designed to provide continuous, at-a-glance glucose measurement, recording, and alerts regarding hypo- and hyperglycemic glucose excursions. In contrast with other approaches that may require calibration multiple-times-per-day, system calibration checks of the GlySens sensor are designed to be required only infrequently, freeing users from the need for burdensome care and maintenance. For people living with diabetes, the GlySens implantable continuous glucose monitoring system (the GlySens ICGMTM system) is intended to provide a means for easy, unobtrusive, worry-free glucose monitoring, and empower users by providing the information they need, while freeing them to live life on their own terms. The GlySens ICGM system is currently undergoing clinical evaluation; initial human implant trials have been completed, and preparations for additional human trials are underway.
What Others Say
“My impression would be that most physicians and patients would gravitate toward this system because it would be easier for them.”Pediatric Endocrinologist, Rady Children's Hospital
“Continuous glucose monitors are very helpful, but the key thing is that you have to wear them, and that’s a big challenge for many people…the idea of having a one-year sensor that is implanted is very, very appealing.”Researcher, JDRF
“The GlySens device represents a potentially major technological leap…”Professor, The Scripps Research Institute
GlySens ICGM: No through-the-skin or skin-adhered components
With the GlySens ICGM approach, there are no frequent needle-based sensor insertions, and no need for maintenance of through-the-skin or skin-attached components. After implantation of the ICGM sensor, the GlySens system is intended to work continuously, with the sensor designed to operate for 365 days or more. Learn more »